Physician profile
Rupert Patel
NPI 1528032042
$10,890.08
in general payments reported to CMS, 2019-2025
32 companies · $1,148 in 2025
The $1,148 reported for 2025 was more than what 81% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,557 · 2020: $745 · 2021: $1,091 · 2022: $2,544 · 2023: $1,152 · 2024: $1,653 · 2025: $1,148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,929 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,928.59 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,441.76 | 2019-2024 | Farxiga, Lokelma |
| Horizon Therapeutics Plc | $1,589.35 | 2021-2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $1,040.51 | 2021-2025 | |
| Fresenius USA Marketing, INC. | $538.57 | 2019-2025 | 2008t Bluestar Hemodialysis Machine, Velphoro, 2008t Bluestar Hemodialysis Machine |
| Boehringer Ingelheim Pharmaceuticals, INC. | $531.29 | 2019-2025 | Jardiance |
| Mallinckrodt Hospital Products INC. | $514.20 | 2020-2025 | Acthar |
| Akebia Therapeutics INC | $471.67 | 2020-2025 | Vafseo, Auryxia |
| Amgen INC. | $434.16 | 2019-2025 | Tavneos, Krystexxa |
| Glaxosmithkline, LLC. | $419.77 | 2022-2024 | Benlysta, Jesduvroq |
| Lilly USA, LLC | $371.56 | 2019-2025 | Jardiance |
| Vifor Pharma, INC. | $309.73 | 2019-2023 | Veltassa |
| Boston Scientific Corporation | $278.58 | 2020-2022 | |
| Mallinckrodt Enterprises LLC | $259.45 | 2019 | |
| Ardelyx, INC. | $258.81 | 2023-2025 | Ibsrela, Xphozah 30 Mg |
| Novartis Pharmaceuticals Corporation | $250.68 | 2023-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nxstage Medical, INC. | $141.99 | 2025 | Liberty Select Cycler |
| Janssen Pharmaceuticals, INC | $125.00 | 2019 | |
| Cardinal Health 108 LLC | $124.00 | 2024 | |
| Novo Nordisk INC | $117.44 | 2019-2025 | |
| Abbvie INC. | $107.94 | 2020 | |
| Sanofi-Aventis U.S. LLC | $102.98 | 2019 | |
| Opko Pharmaceuticals, LLC | $88.99 | 2019-2024 | Rayaldee |
| Ani Pharmaceuticals, INC. | $76.95 | 2022-2023 | Purified Cortrophin Gel |
| Otsuka America Pharmaceutical, INC. | $68.52 | 2020-2021 | |
| Gilead Sciences, INC. | $52.58 | 2020 | |
| Genzyme Corporation | $40.04 | 2022-2023 | |
| Cormedix INC. | $28.14 | 2024 | Defencath |
| Apellis Pharmaceuticals, INC. | $27.16 | 2025 | Empaveli |
| Travere Therapeutics, INC. | $21.80 | 2022-2023 | |
| Scpharmaceuticals INC. | $21.02 | 2025 | |
| Outset Medical INC | $19.80 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rupert Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.